Curcumin-loaded nanoparticles: a novel therapeutic strategy in treatment of central nervous system disorders

Curcumin as a hydrophobic polyphenol is extracted from the rhizome of . Curcumin is widely used as a dietary spice and a topical medication for the treatment of inflammatory disorders in Asia. This compound also possesses remarkable anti-inflammatory and neuroprotective effects with the ability to p...

Full description

Saved in:
Bibliographic Details
Published in:International journal of nanomedicine 2019-06, Vol.14, p.4449-4460
Main Authors: Yavarpour-Bali, Hanie, Ghasemi-Kasman, Maryam, Pirzadeh, Marzieh
Format: Article
Language:English
Subjects:
Alzheimer's disease
Amyotrophic lateral sclerosis
Anti-inflammatory agents
Bioavailability
Central nervous system
Central nervous system diseases
Clinical trials
Curcumin
Drug delivery systems
Epilepsy
Health aspects
Huntington's disease
Multiple sclerosis
Nanoparticles
Nervous system diseases
Review
Water Solubility
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Curcumin as a hydrophobic polyphenol is extracted from the rhizome of . Curcumin is widely used as a dietary spice and a topical medication for the treatment of inflammatory disorders in Asia. This compound also possesses remarkable anti-inflammatory and neuroprotective effects with the ability to pass from the blood brain barrier. Based on several pharmacological activities of curcumin, it has been introduced as an ideal candidate for different neurological disorders. Despite the pleiotropic activities of curcumin, poor solubility, rapid clearance and low stability have limited its clinical application. In recent years, nano-based drug delivery system has effectively improved the aqueous solubility and bioavailability of curcumin. In this review article, the effects of curcumin nanoparticles and their possible mechanism/s of action has been elucidated in various central nervous system (CNS)-related diseases including Parkinson's disease, Huntington disease, Alzheimer's disease, Multiple sclerosis, epilepsy and Amyotrophic Lateral Sclerosis. Furthermore, recent evidences about administration of nano-curcumin in the clinical trial phase have been described in the present review article.
ISSN:1178-2013
1176-9114
1178-2013
DOI:10.2147/IJN.S208332